(HealthDay News) — For premenopausal women with hormone receptor-negative early breast cancer treated with chemotherapy, goserelin can preserve ovarian function, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 30–June 3 in Chicago.
Halle C.F. Moore, MD, of the Cleveland Clinic, and colleagues conducted a multicenter trial involving premenopausal women aged 18–49 years with operable stage I, II, or IIIA estrogen and progesterone receptor-negative breast cancer. Participants were randomized to receive standard chemotherapy (131 patients) or chemotherapy plus goserelin (126 patients).
The researchers found that at two years, the percentage of women who had stopped menstruating or had elevated levels of follicle stimulating hormone was 45% for women in the standard chemotherapy group and 20% in the goserelin group. Furthermore, the pregnancy rate was 21% in the goserelin group compared with 11% in the standard chemotherapy group. At four years, disease-free survival was 89% in the goserelin group and 78% in the chemotherapy group, while overall survival was 92 and 82%, respectively.
“We found that, in addition to reducing the risk of early menopause, and all of the symptoms that go along with menopause, goserelin was very safe and may even improve survival,” a coauthor said in a statement. “I think these findings are going to change our clinical practice.”
The study was partially funded by AstraZeneca, the manufacturer of goserelin.